Show simple item record

dc.contributor.authorSharp, A.
dc.contributor.authorWilliams, A.
dc.contributor.authorBlagden, S. P.
dc.contributor.authorPlummer, E. R.
dc.contributor.authorHochhauser, D.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorPacey, S.
dc.contributor.authorEvans, T. R. J.
dc.contributor.authorWhelan, S.
dc.contributor.authorNandakumar, S.
dc.contributor.authorRogers, S.
dc.contributor.authorJameson, K. L.
dc.contributor.authorBasile, F. G.
dc.contributor.authorDe Bono, J. S.
dc.contributor.authorArkenau, H. T.
dc.date.accessioned2022-11-30T10:21:31Z
dc.date.available2022-11-30T10:21:31Z
dc.date.issued2022en
dc.identifier.citationSharp A, Williams A, Blagden SP, Plummer ER, Hochhauser D, Krebs M, et al. A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304856.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.TPS2691en
dc.identifier.urihttp://hdl.handle.net/10541/625827
dc.titleA first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignanciesen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Suttonen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record